Glutamate and Addiction

463 Pages·2003·5.64 MB·English

by  Barbara H. Herman

G
LU TA M ATE
and
A
DDIC T ION
EDITED BY
B H. H ,
ARBARA ERMAN PhD
-
CO EDITED BY
J F ,
ERRY RANKENHEIM PhD
R Z. L ,
AYE ITTEN PhD
P H. S ,
HILIP HERIDAN MD
F F. W ,
ORREST EIGHT MD
S R. Z ,
TEVEN UKIN MD
HUMANA PRESS
G A
LUTAMATE AND DDICTION
C ontemporary
C linical
Series Editors:
Ralph Lydic and
N euroscience
Helen A. Baghdoyan
Genetics and Genomics of Neurobehavioral Disorders, edited by Gene S.
Fisch, 2003
Sedation and Analgesia for Diagnostic and Therapeutic Procedures, edited
by Shobha Malviya, Norah N. Naughton, and Kevin K. Tremper, 2003
Neural Mechanisms of Anesthesia, edited by Joseph F. Antognini,
Earl E. Carstens, and Douglas E. Raines, 2002
Glutamate and Addiction
edited by Barbara Herman, 2002
Molecular Mechanisms of Neurodegenerative Diseases
edited by Marie-Françoise Chesselet, 2000
Contemporary Clinical Neuroscience
G A
LUTAMATE AND DDICTION
Edited by
B H. H ,
ARBARA ERMAN PhD
Clinical Medical Branch, Division of Treatment Research and Development
National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Bethesda, MD
Coeditors
Jerry Frankenheim, PhD
Pharmacology, Integrative & Cellular Neurobiology Research Branch (PICNRB)
Division of Neuroscience & Behavioral Research (DNBR), National Institute on Drug Abuse (NIDA)
National Institutes of Health (NIH), Bethesda, MD
Raye Z. Litten, PhD
Treatment Research Branch, Division of Clinical and Prevention Research
National Institute on Drug Abuse (NIAAA), National Institutes of Health (NIH), Bethesda, MD
Philip H. Sheridan,
MD
Division of Neuropharmacological Drug Products, Center for Drug Evaluation and Research
Office of Drug Evaluation I, Food and Drug Administration, Rockville, MD
Forrest F. Weight,
MD
Laboratory of Molecular and Cellular Neurobiology, Division of Intramural Clinical and Biological
Research, National Institute on Drug Abuse (NIAAA) National Institutes of Health (NIH)
Bethesda, MD
Steven R. Zukin,
MD
Division of Treatment Research and Development, National Institute on Drug Abuse (NIDA)
National Institutes of Health (NIH), Bethesda, MD
HUMANA PRESS TOTOWA, NEW JERSEY
© 2003 Humana Press Inc.
999 Riverview Drive, Suite 208
Totowa, New Jersey 07512
www.humanapress.com
All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or
by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission
from the Publisher.
The content and opinions expressed in this book are the sole work of the authors and editors, who have warranted due
diligence in the creation and issuance of their work. The publisher, editors, and authors are not responsible for errors
or omissions or for any consequences arising from the information or opinions presented in this book and make no
warranty, express or implied, with respect to its contents.
Due diligence has been taken by the publishers, editors, and authors of this book to assure the accuracy of the
information published and to describe generally accepted practices. The contributors herein have carefully checked to
ensure that the drug selections and dosages set forth in this text are accurate and in accord with the standards accepted at
the time of publication. Notwithstanding, as new research, changes in government regulations, and knowledge from
clinical experience relating to drug therapy and drug reactions constantly occurs, the reader is advised to check the product
information provided by the manufacturer of each drug for any change in dosages or for additional warnings and contrain-
dications. This is of utmost importance when the recommended drug herein is a new or infrequently used drug. It is the
responsibility of the treating physician to determine dosages and treatment strategies for individual patients. Further it is
the responsibility of the health care provider to ascertain the Food and Drug Administration status of each drug or device
used in their clinical practice. The publisher, editors, and authors are not responsible for errors or omissions or for any
consequences from the application of the information presented in this book and make no warranty, express or implied,
with respect to the contents in this publication.
Cover design by Patricia F. Cleary.
For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above
address or at any of the following numbers: Tel.: [phone];Fax: [phone]; E-mail: [email protected] or visit
our website: http://humanapress.com
The opinions expressed herein are the views of the authors and may not necessarily reflect the official policy of the
National Institute on Drug Abuse or any other parts of the US Department of Health and Human Services. The US
Government does not endorse or favor any specific commercial product or company. Trade, proprietary, or company
names appearing in this publication are used only because they are considered essential in the context of the studies
reported herein.
This publication is printed on acid-free paper. ∞
ANSI Z39.48-1984 (American National Standards Institute) Permanence of Paper for Printed Library Materials.
Photocopy Authorization Policy:
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted
by Humana Press Inc., provided that the base fee of US $8.00 per copy, plus US $00.25 per page, is paid directly to the
Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been
granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Humana
Press Inc. The fee code for users of the Transactional Reporting Service is: [0-89603-879-3/03 $10.00 + $00.25].
Printed in the United States of America. 10 9 8 7 6 5 4 3 2 1
Library of Congress Cataloging-in-Publication Data
Glutamate and addiction / edited by Barbara H. Herman; coeditors, Jerry Frankenheim...[et al.].
p.;cm.–(Contemporary clinical neuroscience)
Includes bibliographical references and index.
ISBN 0-89603-879-3 (alk. paper)
1. Substance abuse–Pathophysiology. 2. Glutamic acid–Physiological effect. I. Herman, Barbara H. II.
Frankenheim, Jerry. III. Series.
[DNLM: 1. Substance-Related Disorders–physiopathology. 2. Glutamates–pharmacology. 3. Receptors,
Glutamates–physiology. WM 270 G567 2002]
RC564.G585 2002
616.86–dc21 2002190242
Acknowledgments
This book is dedicated to our families and collaborators who contributed and sup-
ported this effort to characterize the role of glutamatergic systems in addiction disorders
and to develop new technologies for the treatment of these brain disorders. This book is
also dedicated to Dr. Marian Fischman who died on October 23, 2001 during the final
review phase of this book. Dr. Fischman’s contributions to the medications development
of cocaine and opiate addiction were an outstanding influence in understanding the
biology and treatment of addiction disorders. Finally, this book is dedicated to the phy-
sicians Lawrence Kelley, MD, Jacqueline R. Honig, MD, Marc S. Myerson, MD, and the
countless other valued medical personnel who brought one of us back from a near death
experience during its creation.
To Alexandra Samantha Herman, Robert H. Herman, Anita S. Herman
And our families
BHH, JF, RL, FW, SZ

Preface
AssemblingGlutamate and Addiction was a two-and-a-half year labor of love. As
editors, we all had the same goal in mind and pursued this with a fierce dedication. We
felt that it was now time for a volume clarifying for the first time the relationship between
glutamatergic systems and addiction. The past decade has seen a steady and escalating
progression of scientific advances that have implicated a pivotal role of glutamatergic
systems in cocaine, opiate, and alcohol dependence––both the etiology of these disorders
and their treatment. As editors, we met as a group several times a year to discuss the
progress and the ever emerging direction of the book. As senior editor, I am personally
indebted to the superb job of the coeditors attracting the very best scientists in this field
to contribute their important papers to this book.
To Philip H. Sheridan, MD of the Food and Drug Administration (FDA), for his mar-
velous ability to attract internationally known scientists to contribute to the first section
of the book on the basic physiology and pharmacology of glutamate. The five stellar
chapters in this section include ones by Borges and Dingledine; Witkin, Kaminski and
Rogawski; Choi and Snider; Sanchez and Jensen; and Kaul and Lipton. A special thank
you to Michael A. Rogawski, MD,PhD, Epilepsy Research Section, NINDS, NIH for being
an early and avid supporter of this effort and bringing to our attention valuable contribu-
tors to this book. It is our hope that these five introductory chapters will provide a level
playing field for all readers of this book to upgrade their basic understanding of glutamate
before proceeding to the other research chapters focused on the relationship between
glutamate and various addictive disorders.
To Jerry Frankenheim, PhD of the National Institute on Drug Abuse, the National
Institutes of Health (NIH) for his wonderful role, as senior editor of Section II, in illus-
trating the role of glutamatergic systems in stimulant drugs of abuse including cocaine,
amphetamine, and methamphetamine. Dr. Frankenheim displayed considerable care in
editing this section. In addition, I am personally indebted to Dr. Frankenheim for his
seamless job in serving as Acting Senior Editor of this volume for a two-month period
when I was unavailable for this task. Section II is a truly remarkable part of the book in
its thoroughness in covering virtually every aspect of the role of glutamate in stimulant
drugs of abuse, with outstanding chapters by Pert, Post, and Weiss; Karler, Thai, and
Calder; Wolf; Baker, Cornish, and Kalivas; Wang, Mao, and Lau; Pulvirenti; Vezina and
Suto; Cadet; Burrows and Yamamoto; Itzhak, Martin, and Ali; Matsumoto and Pouw;
Bisaga and Fischman; and Epping-Jordan. As we state in our dedication of this book, this
effort also coincided with the tragic death of one of our beloved colleagues in the addic-
tion field, Marian Fischman, PhD of Columbia University School of Medicine. Dr. Fis-
chman was a vibrant human being, and one of the most vital forces in the research field
of addiction medicine. A personal thank you to Adam Bisaga, MD who took over the task
of writing and editing this chapter with Dr. Fischman in an extremely gracious and
responsible fashion in the face of tragic circumstances.
We are extremely grateful to the authors who contributed to the valued third section
of the book on glutamate and opiate drugs of abuse including heroin. The world-renown
scientists in this section included Mao; Trujillo; Popik; and Rasmussen. An overview of
this important topic is provided by Jianren Mao, MD,PhD of Harvard University School
vii
viii Preface
of Medicine. It is of interest to note that the researchers in this section were some of the
first to provide evidence of a relationship between glutamate and various aspects of the
addiction process.
In the final section, the relationship between glutamate and alcohol abuse and alcohol-
ism is explored. Our superb editors of Section IV are Forrest F. Weight, MD and Raye
Litten,PhD, both of the National Institute of Alcohol Abuse and Alcoholism (NIAAA).
Personally, I am particularly grateful for the continuous role provided by Dr. Litten, who
managed to come to virtually every editorial meeting across building lines and to quickly
get his section collated into a deliverable form to our publisher, Humana Press.
I would like to thank Craig Adams and Elyse O’Grady of Humana Press for their
superb editorial and publishing skills and their tireless efforts in cheering this effort on
to its completion. Craig and Elyse supported this effort from the beginning and until its
completion, with a compassion and expertise that I will forever admire.
Finally, I would like to thank my institute, the National Institute on Drug Abuse, NIH,
for being supremely generous in allowing me the time to pursue this effort for the last two
and a half years. Particular thanks goes to Alan Leshner, Ph.D., former Director, NIDA,
Glen R. Hanson, PhD,DDS, current and Acting Director, NIAA, Frank Vocci, PhD, Director,
Division of Treatment Research and Development (DTR&D), NIDA and Ahmed Elkashef,
MD, Chief, Clinical Medical Branch (CMB), DTR&D, NIDA for permitting this effort to
occur. We also thank the institute directors of NIAAA, Enoch Gordis, MD (former director)
and the present top official of the FDA Bernard A. Schwertz, DVM,PhD, Acting Principal
Deputy Commissioner and the past commissioner of the FDA, Jane E. Henney, MD for
enabling the participation of individuals from their respective institutions.
I am personally touched by the numerous cards, letters and flowers that I received from
family, friends, professional colleagues, and folks from Humana while in the hospital.
Our interest in glutamatergic systems and drug abuse disorders stems back to at least
1991, when the first preclinical evidence was presented for a role of this system in the
development of opiate tolerance and withdrawal (cf. 1, 2). Indeed, a few years earlier,
research in the late 1980s suggested a role of glutamate in stimulant drug addiction (3).
From there, we as a group launched several efforts to try to synthesize the knowledge
base that was quickly accumulating in this exciting area. Thanks to the efforts of the
National Institutes of Health (NIH) and the Food and Drug Administration (FDA),
approaches to understanding the biological and behavioral basis of drug addiction and
developing new modalities for the treatment of drug addiction are now attaining some
level of consistency across the world. A highlight in this trend for unification in theory
and practice, is illustrated by the conceptual writings of Alan I. Leshner, PhD former
Director, National Institute on Drug Abuse, who has tirelessly pioneered to increase the
research and scientific basis for understanding drug addiction as a disorder of the brain
(e.g., 4, 5). A similar emphasis on drug abuse as a brain disorder is noted in the very basic
preclinical research of Stephen E. Hyman, MD, former Director, National Institute on
Mental Health (e.g., 6, 7). Similarly, in a monthly letter developed by the National
Institute on Alcohol Abuse and Treatment (NIAAA), Enoch Gordis, MD, former Direc-
tor, NIAAA has describe numerous scientific advances detailing the role of various
biochemical systems in alcohol dependence and the role of medication treatment in
alcohol dependence (cf., 8, 9). An esteemed partner in this endeavor is Jane Henney, MD,
former Commissioner, FDA whose institute is responsible for making certain that the
medications that are developed for this indication are both efficacious and safe. We very
Preface ix
much value the superb contributions of the authors in Section IV on glutamate and
alcohol, who include Peoples; Crew, Rudolph, and Chandler; Becker and Redmond;
Krystal, Petrakis, D’Souza, Mason, and Trevisan; Zieglgänsberger, Rammes, Spanagel,
Danysz, and Parsons; Pasternak and Kolesnikov; and Potgieter. We all work together
with these institutes and with the creative and brilliant scientists who undertake both the
preclinical and clinical research to develop a rigorous science of drug addiction. It is our
hope that this research will result in innovative treatments for drug abuse and addiction,
and for understanding the basis of these disorders in the central nervous system.
The job of characterizing the role of glutamatergic systems in addiction disorders is now
off to a solid beginning. With the recent advance and approval of glutamatergic antago-
nists for the indication of alcohol abuse and addiction in a variety of European countries,
we have already started to witness some clinical payoff for the superbly innovative and
thorough research of both preclinical and clinical sciences. We hope that this effort will
launch a new decade starting in the year 2001, that will see yet even further advances in
the glutamatergic field, both in the etiology and treatment of addiction disorders.
Barbara H. Herman, PhD
References
1. Herman, B.H., Vocci, F., Bridge, P. The effects of NMDA receptor antagonists and nitric
oxide synthase inhibitors on opioid tolerance and withdrawal. Neuropsychopharmacology13:
269–292, 1995.
2. Herman, B.H. and O’Brien, C.P. Clinical medications development for opiate ad-
diction: focus on nonopioids and opioid antagonists for the amelioration of opiate with-
drawal symptoms and relapse prevention. Seminars in Neuroscience9: 158–172, 1997.
3. Karler, R., et al., Blockade of “reverse tolerance” to cocaine and amphetamine by
MK-801.Life Sci 45: 599–606, 1989.
4. Leshner A.I., Koob G.F. Drugs of abuse and the brain. Proc Assoc Am Physicians
111:99–108, 1999.
5. Leshner A.I. Addiction is a brain disease, and it matters. Science278: 45–47, 1997.
6. Hyman S.E., Hyman S.E., Malenka R.C. Addiction and the brain: the neurobiology
of compulsion and its persistence. Nat Rev Neurosci.2: 695–703, 2001.
7. Berke J.D., Hyman S.E. Addiction, dopamine, and the molecular mechanisms of
memory.Neuron25: 515–532, 2000.
8. Gordis E. Advances in research on alcoholism and what they promise for future
treatment and prevention. Med Health RI82:121, 1999.
9. Gordis E. The neurobiology of alcohol abuse and alcoholism: building knowledge,
creating hope. Drug Alcohol Depend.51:9–11, 1998.